Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06559059

Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs

The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer Diagnosis Breast Cancer Diagnosis Breast Diseases Breast Neoplasms Colonic Diseases Colorectal Cancer (Diagnosis) Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Disease Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Prostate Cancer Diagnosis Rectal Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

VA New York Harbor Healthcare System - Brooklyn, Brooklyn, New York, United States

Loading trial locations.

About this study

Study staff will use the Veterans Health Information Systems and Technology Architecture (VistA), the VA health information technology system, to identify eligible patients at VA sites based on listed inclusion and exclusion criteria. Patient records will be observed of Veterans with a new cancer diagnosis of the lung, prostate, breast, or colon and a telehealth visit utilizing the VA National TeleOncology Service (NTO).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients Inclusion Criteria:

  • A Veteran
  • Aged 18 years or older
  • Newly diagnosed with lung, prostate, breast, or colon cancer within 3 months of telemedicine visit
  • Engaged in an oncology visit during the 36-month analysis period at a Veterans Affairs Medical Center (VAMC) location.

VAMC Providers and Staff Inclusion Criteria:

  • Provider or staff member at one of the VAMC locations including physicians, nurse practitioners, physicians' assistants, and nurses caring for Veterans
  • Providers or staff members having helped provide care for at least 5 Veterans with cancer in the previous 6 months at a VAMC location

Patients Exclusion Criteria:

  • Veterans who have not seen any providers in the VA within the past year
  • Patients previously diagnosed with lung, prostate, breast, or colon cancer
  • Pregnant patients

VAMC Providers and Staff Exclusion Criteria:

  • Providers or staff members who do not help treat Veterans with specified cancers in oncology at the VA

Treatment and study plan

National TeleOncology

Behavioral

Medical and/or subspecialty oncology care offered via facility-to-facility telehealth as an alternative to usual in-person care at the nearest VA or community oncology care setting offering similar services.

Primary outcomes

  1. Number of raw telehealth visits

    Time frame: Post-NTO implementation (up to 3 months)

    Telehealth utilization among Veterans with cancer will be measured through raw telehealth visit counts.

  2. Fraction of patients engaging in at least one telehealth visit

    Time frame: Post-NTO implementation (up to 3 months)

    Telehealth utilization among Veterans with cancer will be measured by fraction of patients engaging in at least one telehealth visit.

Secondary outcomes

  1. Change in provider level Quality Oncology Practice Initiative (QOPI) score

    Time frame: Pre-implementation, post-NTO implementation (up to 3 months)

    The quality of care of the intervention will be evaluating utilizing the American Society of Clinical Oncology Practice Initiative (QOPI) performance measures. The scale consists of 26 performance measures assessed at the patient, provider, and facility levels. Each cancer care provider will have his or her patient QOPI measures aggregated together for a provider level QOPI score. Our primary interest is the difference in QOPI score by intervention condition, as estimated by the fixed-effect coefficient for the intervention indicator variable. Scores of 75% or more indicate the standard is met, scores less than 75% indicate the standards have not been met. An increase in the QOPI score indicates improvement.

  2. Time of consultation to time of first appointment

    Time frame: Pre-implementation, post-NTO implementation (up to 3 months)

    Time to care will be measured through time of consultation to time of first appointment.

  3. Time of consultation to time of first treatment

    Time frame: Pre-implementation, post-NTO implementation (up to 3 months)

    Time to care will be measured through time of consultation to time of first treatment.

  4. Average total cost for cancer diagnosis, treatment and downstream HealthCare utilization

    Time frame: Post-NTO implementation (up to 3 months)

Study contacts

Contact information is provided by the study sponsor or research team.

Janeth Juarez Padilla

CONTACT

[email protected]

646-501-3588

Navid Dardashti

CONTACT

[email protected]

201-906-7713

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Aug 19, 2024
Registry last updated
Jun 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.